David M Meredith
Overview
Explore the profile of David M Meredith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1372
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghosh H, Patel R, Claus E, Gonzalez Castro L, Wen P, Ligon K, et al.
Neuro Oncol
. 2024 Nov;
PMID: 39584448
Background: Molecular features have been incorporated alongside histologic criteria to improve glioma diagnostics and prognostication. CDKN2A/B homozygous-loss associates with worse survival in IDH1/2-mutant astrocytomas (IDHmut-astrocytomas), the presence of which denotes...
2.
Iwamoto F, Tanguturi S, Nayak L, Wang T, Desai A, Lustig R, et al.
Clin Cancer Res
. 2024 Nov;
31(2):316-327.
PMID: 39513953
Purpose: Radiotherapy may enhance antitumor immune responses by several mechanisms, including induction of immunogenic cell death. We performed a phase 2 study of pembrolizumab with re-irradiation in patients with recurrent...
3.
Tobochnik S, Regan M, Dorotan M, Reich D, Lapinskas E, Hossain M, et al.
Clin Cancer Res
. 2024 Nov;
30(23):5365-5373.
PMID: 39499201
Purpose: Glutamatergic neuron-glioma synaptogenesis and peritumoral hyperexcitability promote glioma growth in a positive feedback loop. The objective of this study was to evaluate the feasibility and estimated effect sizes of...
4.
Paes T, Buelvas Mebarak J, Magnotto J, Stamatiades G, Kuang Y, Paweletz C, et al.
J Clin Endocrinol Metab
. 2024 Sep;
PMID: 39238355
Context And Objective: The genetic profile of prolactinomas remains poorly understood. Our objective is to identify somatic genetic alterations associated with prolactinomas and to report the identification of an activating...
5.
Ghosh H, Patel R, Woodward E, Greenwald N, Bhave V, Maury E, et al.
Neuro Oncol
. 2024 Aug;
27(1):195-208.
PMID: 39164213
Background: With the significant shift in the classification, risk stratification, and standards of care for gliomas, we sought to understand how the overall survival of patients with these tumors is...
6.
Bernstock J, Karandikar P, Chen J, Seidlitz J, Friedman G, Meredith D, et al.
Front Surg
. 2024 Jun;
11:1356660.
PMID: 38840975
Intrinsic, expansile pontine tumors typically occur in the pediatric population. These tumors characteristically present as diffuse intrinsic pontine glioma (DIPG), which is now considered as diffuse midline glioma (DMG), H3K27-mutated...
7.
Meredith D, Pisapia D
Continuum (Minneap Minn)
. 2023 Dec;
29(6):1638-1661.
PMID: 38085892
Objective: The classification of brain tumors is a rapidly evolving field that requires extensive integration of molecular diagnostic findings from an expanding set of platforms and assays. This article summarizes...
8.
Gestrich C, Grieco K, Lidov H, Baird L, Fehnel K, Yeo K, et al.
J Neuropathol Exp Neurol
. 2023 Dec;
83(1):30-35.
PMID: 38037182
Large-scale sequencing led to the identification of driver molecular alterations such as FGFR1 and BRAF in occasional diffuse midline gliomas (DMGs) H3K27-mutant but their significance has not been completely explored....
9.
Rahman R, Trippa L, Lee E, Arrillaga-Romany I, Fell G, Touat M, et al.
J Clin Oncol
. 2023 Sep;
41(36):5524-5535.
PMID: 37722087
Purpose: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for...
10.
Meredith D, Cooley L, Dubuc A, Morrissette J, Sussman R, Nasrallah M, et al.
Mod Pathol
. 2023 Aug;
36(11):100294.
PMID: 37532182
Gliomas harboring oncogenic ROS1 alterations are uncommon and primarily described in infants. Our goal was to characterize the clinicopathological features and molecular signatures of the full spectrum of ROS1 fusion-positive...